Stiff -person syndrom
Authors:
P. Potužník; J. Vejskal; R. Kotas
Authors place of work:
Neurologická klinika LF UK a FN Plzeň
Published in the journal:
Cesk Slov Neurol N 2021; 84(6): 581-582
Category:
Letters to Editor
doi:
https://doi.org/10.48095/cccsnn2021581
Zdroje
1. Matsui N, Tanaka K, Kaji R. Stiff-Person syndrome and related autoantibodies. Brain Nerve 2018; 70 (4): 357–362. doi: 10.11477/mf.1416201008.
2. Sexauer W, Woodford M, Pack K et al. Dyspnea in patients with Stiff-Person syndrome. Am J Med Sci 2019; 358 (4): 268–272. doi: 10.1016/j.amjms.2019.07.007.
3. Li Y, Thakore N. An appraisal of electrodiagnostic studies in Stiff-Person syndrome. J Clin Neuromuscul Dis 2020; 22 (2): 84–89. doi: 10.1097/CND.0000000000000302.
4. Folli F, Solimena M, Cofiell R et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328 (8): 546–551. doi: 10.1056/NEJM199302253280 805.
5. Rakocevic G, Floeter MK. Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes. Muscle Nerve 2012; 45 (5): 623–634. doi: 10.1002/mus.23234.
6. Chapel H, Haeney M, Mishab S et al. Základy klinické imunologie. 6. vyd. Praha: Triton 2018.
7. Muñoz-Lopetegi A, de Bruijn MA, Boukhrissi S et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm 2020; 7 (3): e696. doi: 10.1212/NXI.0000000000000696.
8. Ortiz JF, Ghani MR, Morillo Cox Á et al. Stiff-Person syndrome: a treatment update and new directions. cureus 2020; 12 (12): e11995. doi: 10.7759/cureus.11995.
Štítky
Paediatric neurology Neurosurgery NeurologyČlánok vyšiel v časopise
Czech and Slovak Neurology and Neurosurgery
2021 Číslo 6
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
Najčítanejšie v tomto čísle
- Stiff -person syndrom
- Normotenzní hydrocefalus
- Synukleinopatie a jejich laboratorní biomarkery
- Perorální kladribin v léčbě roztroušené sklerózy – data z celostátního registru ReMuS®